JP2017523189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523189A5 JP2017523189A5 JP2017505081A JP2017505081A JP2017523189A5 JP 2017523189 A5 JP2017523189 A5 JP 2017523189A5 JP 2017505081 A JP2017505081 A JP 2017505081A JP 2017505081 A JP2017505081 A JP 2017505081A JP 2017523189 A5 JP2017523189 A5 JP 2017523189A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- stage
- patent document
- dry powder
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 77
- 239000000843 powder Substances 0.000 claims description 40
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 33
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 32
- 239000002245 particle Substances 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 16
- 238000012377 drug delivery Methods 0.000 claims description 13
- 230000000302 ischemic effect Effects 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 208000007536 Thrombosis Diseases 0.000 claims description 5
- 230000001052 transient effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 150000003904 phospholipids Chemical class 0.000 claims 8
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 7
- 239000008347 soybean phospholipid Substances 0.000 claims 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 6
- 230000000241 respiratory effect Effects 0.000 claims 6
- 208000005189 Embolism Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- 229960003009 clopidogrel Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 8
- 208000006011 Stroke Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- JJBCTCGUOQYZHK-ZSCHJXSPSA-N 2-acetyloxybenzoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.CC(=O)OC1=CC=CC=C1C(O)=O JJBCTCGUOQYZHK-ZSCHJXSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000010906 Cyclooxygenase 1 Human genes 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000008369 airway response Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462031811P | 2014-07-31 | 2014-07-31 | |
| US62/031,811 | 2014-07-31 | ||
| PCT/US2015/043128 WO2016019253A1 (en) | 2014-07-31 | 2015-07-31 | Dry powder formulations for inhalation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523189A JP2017523189A (ja) | 2017-08-17 |
| JP2017523189A5 true JP2017523189A5 (https=) | 2018-09-13 |
| JP6850524B2 JP6850524B2 (ja) | 2021-03-31 |
Family
ID=55218356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505081A Active JP6850524B2 (ja) | 2014-07-31 | 2015-07-31 | 吸入用の乾燥粉末製剤 |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP4218734A1 (https=) |
| JP (1) | JP6850524B2 (https=) |
| KR (2) | KR102666667B1 (https=) |
| CN (2) | CN107072947A (https=) |
| AU (2) | AU2015296142A1 (https=) |
| CA (1) | CA2991760C (https=) |
| DK (1) | DK3179986T3 (https=) |
| ES (1) | ES2942297T3 (https=) |
| PL (1) | PL3179986T3 (https=) |
| WO (1) | WO2016019253A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016176552A1 (en) | 2015-04-30 | 2016-11-03 | Otitopic Inc. | Dry power formulations for inhalation |
| US10568894B2 (en) | 2016-06-03 | 2020-02-25 | Otitopic Inc. | Dry powder formulations for inhalation |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| KR102681843B1 (ko) * | 2017-09-22 | 2024-07-05 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
| EP4311566A1 (en) | 2022-07-28 | 2024-01-31 | Vectura Inc. | An inhaler comprising a retention element |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
| ES2237767T3 (es) | 1995-04-14 | 2005-08-01 | Nektar Therapeutics | Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada. |
| MX9707862A (es) | 1995-04-14 | 1997-11-29 | Glaxo Wellcome Inc | Inhalador de dosis medida para el propionato de fluticasona. |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| EP1013269A4 (en) * | 1997-06-06 | 2002-02-20 | Shionogi & Co | IMPROVEMENT OF A DRUG ADMINISTRATION SYSTEM |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| CN1169520C (zh) | 1997-09-29 | 2004-10-06 | 耐科塔医药公司 | 多孔微粒及其使用方法 |
| GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
| WO2000000215A1 (en) | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
| GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
| US7871598B1 (en) * | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| PT1296651E (pt) * | 2000-06-27 | 2008-02-12 | Vectura Ltd | Método para fazer partículas para serem usadas numa composição farmacêutica |
| CA2465675C (en) | 2001-11-20 | 2008-06-10 | Advanced Inhalation Research, Inc. | Improved particulate compositions for pulmonary delivery |
| GB0208609D0 (en) * | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Compositions |
| WO2004030659A1 (en) * | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
| WO2005115341A2 (en) | 2004-05-27 | 2005-12-08 | Advanced Bionutrition Corporation | Microparticles for oral delivery |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| WO2006105167A2 (en) | 2005-03-28 | 2006-10-05 | Pericor Therapeutics, Inc. | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient |
| CA2611741A1 (en) * | 2005-06-13 | 2006-12-28 | Elan Pharma International, Limited | Nanoparticulate clopidogrel and aspirin combination formulations |
| GB0621957D0 (en) | 2006-11-03 | 2006-12-13 | Vectura Group Plc | Inhaler devices and bespoke pharmaceutical compositions |
| WO2009026434A1 (en) | 2007-08-21 | 2009-02-26 | Alkermes, Inc. | Pulmonary pharmaceutical formulations |
| NO2252275T3 (https=) | 2008-02-13 | 2018-04-28 | ||
| CA2759109A1 (en) * | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics |
| GB201102237D0 (en) | 2011-02-09 | 2011-03-23 | Kuecept Ltd | Particle formulation |
| US9216527B2 (en) | 2012-02-09 | 2015-12-22 | G & W Electric Company | Solid-dielectric switch including a molded viewing window |
| EP2819645A2 (en) * | 2012-02-28 | 2015-01-07 | Iceutica Holdings Inc. Bvi | Inhalable pharmaceutical compositions |
| US9757395B2 (en) * | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) * | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| HK1218720A1 (zh) | 2013-04-30 | 2017-03-10 | 欧缇托匹克公司 | 干粉制剂及使用方法 |
| ES2922206T3 (es) | 2014-02-20 | 2022-09-09 | Otitopic Inc | Formulaciones de polvo seco para la inhalación |
-
2015
- 2015-07-31 ES ES15827152T patent/ES2942297T3/es active Active
- 2015-07-31 DK DK15827152.8T patent/DK3179986T3/da active
- 2015-07-31 CN CN201580052364.7A patent/CN107072947A/zh active Pending
- 2015-07-31 EP EP23154329.9A patent/EP4218734A1/en active Pending
- 2015-07-31 CN CN202310193558.5A patent/CN116687887A/zh active Pending
- 2015-07-31 KR KR1020237026168A patent/KR102666667B1/ko active Active
- 2015-07-31 CA CA2991760A patent/CA2991760C/en active Active
- 2015-07-31 KR KR1020177005617A patent/KR102603897B1/ko active Active
- 2015-07-31 WO PCT/US2015/043128 patent/WO2016019253A1/en not_active Ceased
- 2015-07-31 EP EP15827152.8A patent/EP3179986B1/en active Active
- 2015-07-31 JP JP2017505081A patent/JP6850524B2/ja active Active
- 2015-07-31 PL PL15827152.8T patent/PL3179986T3/pl unknown
- 2015-07-31 AU AU2015296142A patent/AU2015296142A1/en not_active Abandoned
-
2020
- 2020-05-26 AU AU2020203437A patent/AU2020203437B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3033142T3 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| US10391078B2 (en) | Methods for the treatment of mast cell related disorders with mast cell stabilizers | |
| JP2017523189A5 (https=) | ||
| JP2021102620A (ja) | 乾燥粉末配合および使用方法 | |
| JP2022137070A5 (https=) | ||
| JP2014514271A (ja) | 頻拍を治療するためのグリコピロラートの使用 | |
| JP2007530620A (ja) | メロキシカムを含む組成物 | |
| JP5542309B2 (ja) | 経口医薬組成物 | |
| Al-Salama et al. | Glycopyrronium/formoterol: a review in COPD | |
| JP6850524B2 (ja) | 吸入用の乾燥粉末製剤 | |
| JP6415536B2 (ja) | ブデソニドおよびフォルモテロールを含む医薬組成物 | |
| Dhoble et al. | Site-specific delivery of inhalable antiangiogenic liposomal dry powder inhaler technology ameliorates experimental pulmonary hypertension | |
| ES2647223T3 (es) | Vapendavir para el alivio de los síntomas del asma en un sujeto que tiene una infección por el VRH | |
| JP5433295B2 (ja) | キサンタンガム被覆水溶性糖類及び圧縮成形製剤 | |
| CN110251473A (zh) | 羟哌吡酮口服缓释制剂 | |
| BRPI0609827A2 (pt) | uso de drogas anti-inflamatórias não esteróides por inalação no tratamento de bronquite aguda e crÈnica | |
| JP2023550407A (ja) | 肺高血圧向けの吸入式イマチニブ | |
| KR102449403B1 (ko) | 부데소니드 및 포르모테롤을 함유하는 약학 조성물 | |
| JP6159128B2 (ja) | 抗ロタウイルス剤 | |
| JP7570499B2 (ja) | 肺炎を予防・治療する薬物におけるポリペプチドの応用 | |
| JP7119650B2 (ja) | 鎮痛剤 | |
| JP4318899B2 (ja) | 抗感冒剤 | |
| JPWO2005063253A1 (ja) | アレルギー症状治療用医薬組成物 | |
| JP2010120932A (ja) | 経口用医薬組成物 | |
| HK40058742B (zh) | 呼吸性疾病的治疗 |